This afternoon we watched Catalent drop -2.4% to a price of $43.2 per share. The large-cap Pharmaceutical company is now trading -13.6% below its average target price of $50.0. Analysts have set target prices ranging from $33.0 to $86.0 per share for Catalent, and have given the stock an average rating of hold.
The stock has an average amount of shares sold short at 5.1%, and a short ratio of 1.33. Only 0.37% of the company's shares are owned by insiders, indicating that management does not have a deep alignment of interest with its shareholders. Finally, we also note that a significant number of institutional investors are invested in the stock, with 105.8% of Catalent's shares being owned by this investor type.
Institutions Invested in Catalent
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2023-03-31 | Vanguard Group, Inc. (The) | 11% | 19,717,749 | $851,806,771 |
| 2023-03-31 | Blackrock Inc. | 8% | 14,315,148 | $618,414,404 |
| 2023-03-31 | Capital World Investors | 7% | 13,403,636 | $579,037,085 |
| 2023-03-31 | T. Rowe Price Investment Management, Inc. | 7% | 12,023,668 | $519,422,466 |
| 2023-03-31 | Janus Henderson Group PLC | 7% | 12,016,486 | $519,112,204 |
| 2023-03-31 | Artisan Partners Limited Partnership | 4% | 7,737,685 | $334,267,997 |
| 2023-03-31 | State Street Corporation | 4% | 7,198,603 | $310,979,655 |
| 2023-03-31 | Veritas Asset Management LLP | 4% | 6,885,115 | $297,436,973 |
| 2023-03-31 | American Century Companies, Inc. | 2% | 4,396,231 | $189,917,182 |
| 2023-03-31 | Leonard Green & Partners, L.P. | 2% | 4,342,441 | $187,593,454 |
Besides an analyst consensus of some upside potential, other market factors point to there being mixed market sentiment on Catalent.
